April 2024

Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open. 2024 Apr 12;10(2):e003912. doi: 10.1136/rmdopen-2023-003912. PMID: 38609322; PMCID: PMC11029242.

Andréasson K, Olofsson T, Lagishetty V, Alrawi Z, Klaassens E, Holster S, Hesselstrand R, Jacobs JP, Wallman JK, Volkmann ERTreatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota. ACR Open Rheumatol. 2024 Apr 23. doi: 10.1002/acr2.11673. Epub ahead of print. PMID: 38653503.

March 2024

Chung SA, Kermani TAImproving on Intuition: Assessing Disease Activity in Takayasu Arteritis. Arthritis Care Res (Hoboken). 2024 Mar 4. doi: 10.1002/acr.25320. Epub ahead of print. PMID: 38433604.

El Aoufy K, Melis MR, Iovino P, Bambi S, Lorini C, Bonaccorsi G, Galetti I, Garbagnati C, Canziani P, Tonolo S, Mitola M, Guiducci S, Furst DE, Matucci-Cerinic M, Rasero L, Bellando-Randone S. The Rising Challenge of Poor Health Literacy of Patients with Systemic Sclerosis: Preliminary Data Identify Important Unmet Needs in an Italian Cohort. Nurs Rep. 2024 Mar 5;14(1):556-565. doi: 10.3390/nursrep14010043. PMID: 38535715; PMCID: PMC10976134.

Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C; Accelerating Medicines Partnership: RA/SLE Network; Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv [Preprint]. 2024 Mar 9:2024.01.14.575609. doi: 10.1101/2024.01.14.575609. PMID: 38293222; PMCID: PMC10827101.

Yokose C, McCormick N, Abhishek A, Dalbeth N, Pascart T, Lioté F, Gaffo A, FitzGerald J, Terkeltaub R, Sise ME, Januzzi JL, Wexler DJ, Choi HK. The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024 Apr;20(4):216-231. doi: 10.1038/s41584-024-01092-x. Epub 2024 Mar 12. PMID: 38472344.

Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, Bhatt DL, Wang C, Mikuls TR, Chen AS, Connell CA, Woolcott JC, Menon S, Chen Y, Lee K, Szekanecz Z. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2024 Mar 13. doi: 10.1002/art.42846. Epub ahead of print. PMID: 38481002.

Wareing N, Wang X, Keyes-Elstein L, Goldmuntz EA, Lyons MA, McSweeney P, Furst DE, Nash RA, Crofford LJ, Welch B, Pinckney A, Mayes MD, Sullivan KM, Assassi S. Myeloablation followed by hematopoietic stem cell transplantation leads to long-term normalization of systemic sclerosis molecular signatures. Arthritis Rheumatol. 2024 Mar 18. doi: 10.1002/art.42847. Epub ahead of print. PMID: 38497141.

Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024 Mar;20(3):196. doi: 10.1038/s41584-024-01085-w. Erratum for: Nat Rev Rheumatol. 2024 Feb;20(2):101-115. PMID: 38302658.

February 2024

Yen EY, Singh DR, Singh RRSteady decrease in systemic sclerosis mortality rates at younger ages over the past five decades. Rheumatology (Oxford). 2024 Feb 1;63(2):466-471. doi: 10.1093/rheumatology/kead233. PMID: 37216898; PMCID: PMC10836968.

Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, Zucchetto M, Huang S, Jennings A, Nihtyanova SI, Denton CP. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2024 Feb 1;63(2):472-481. doi: 10.1093/rheumatology/kead234. PMID: 37228011; PMCID: PMC10836965.

Elfishawi MM, Kaymakci MS, J Achenbach S, S Crowson C, Kermani TA, M Weyand C, J Koster M, Warrington KJ. Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years. RMD Open. 2024 Feb 8;10(1):e003775. doi: 10.1136/rmdopen-2023-003775. PMID: 38331471; PMCID: PMC10860079.

Mannion ML, Xie F, FitzGerald JD, Alexander A, Mudano A, Su Y, Saag KG, Curtis JR. Changes in the Workforce Characteristics of Providers Who Care for Adult Patients With Rheumatologic and Musculoskeletal Disease in the United States. Arthritis Rheumatol. 2024 Feb 25. doi: 10.1002/art.42833. Epub ahead of print. PMID: 38403436.

January 2024

Charles-Schoeman C, Giles JT, Lane NE, Choy E, Furst DE, Vencovský J, Wilson AG, Burmester GR, Coombs D, Penn SK, Khan N, Yee JB, Rahawi K, McInnes IB. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatol Ther. 2024 Feb;11(1):157-175. doi: 10.1007/s40744-023-00624-3. Epub 2024 Jan 5. PMID: 38180720; PMCID: PMC10796877.

Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024 Feb;20(2):101-115. doi: 10.1038/s41584-023-01062-9. Epub 2024 Jan 12. Erratum in: Nat Rev Rheumatol. 2024 Mar;20(3):196. PMID: 38216757.

Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T; ProDERM investigators. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. PMID: 38233885; PMCID: PMC10792872.

Vassileva MT, Suresh V, Chan AC, Akinsete AV, Blanco I, Blazer A, Criscione-Schreiber L, Dowell S, Feldman CH, FitzGerald J, Gilbert M, Hughes G, Husni ME, Kerr G, Kwan O, Mantilla B, Nilson S, Rivadeneira AC, Rodríguez M, Smith BJ, Soulsby WD, Wong SC, Yazdany J, Ross W. Improving Health Equity in Rheumatology Through Workforce Diversification and Support for Health Equity Research and Education. Arthritis Rheumatol. 2024 Jan 19. doi: 10.1002/art.42804. Epub ahead of print. PMID: 38240019.

Lepri G, Bruni C, Tofani L, Moggi-Pignone A, Orlandi M, Tomassetti S, Hughes M, Del Galdo F, Irace R, Distler O, Riccieri V, Allanore Y, Gheorghiu AM, Siegert E, De Vries-Bouwstra J, Hachulla E, Tikly M, Damjanov N, Spertini F, Mouthon L, Hoffmann-Vold AM, Gabrielli A, Guiducci S, Matucci-Cerinic M, Furst D, Bellando-Randone S, Eustar Collaborators. The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database. Diagnostics (Basel). 2024 Jan 30;14(3):295. doi: 10.3390/diagnostics14030295. PMID: 38337811; PMCID: PMC10855256.

Mease PJ, Reddy S, Ross S, Lisse JR, Reis P, Griffing K, Sapin C, Vadhariya A, Furst DEEvaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. 2024 Jan 31;10(1):e003423. doi: 10.1136/rmdopen-2023-003423. PMID: 38296801; PMCID: PMC10831472.

Matz E, Singh RR. Secular trends in mortality from inflammatory muscle diseases over a quarter century. Student Poster session #32924 at the American Association for Advancement of Science (AAAS) annual meeting, New York, 2024.

Sharma R, Yen E, Singh RR. Race/Ethnicity and Rural-Urban Continuum Codes Independently and Interactively Associate with the Odds of Death from Lupus Relative to Deaths from Accident and All Causes: Population-based Study, 2011-2015. Accepted at EULAR 2024, Vienna, Austria.

Matz E, Rajkumar S, Singh RR. No Disproportionate Increase in Mortality Directly Attributed to Dermatopolymyositis During the COVID-19 Pandemic: A Population-Based Study. Accepted at EULAR 2024, Vienna, Austria.

Rajkumar S, Yen E, Chen L, Singh RR. Income, Race/Ethnicity, and Urban-Rural Residential Region as Determinants of Mortality in Lupus Nephritis. Accepted at EULAR 2024, Vienna, Austria.